

Contents

Preface	v
Acknowledgments	vii
Introduction	<i>G. Jollès</i> ix

REVIEW OF PRESENT STATUS OF IMMUNOSTIMULANTS

Immunostimulants: The Western Scene	<i>G. H. Werner</i> 3
Development of Immunostimulants in Japan	<i>I. Azuma</i> 41
Synthetic MDP's, Lipid A's and Their Related Compounds	<i>H. Takada and S. Kotani</i> 57
Biological Activities of a Lipophilic Muramylpeptide (MTP-PE)	<i>G. Schumann</i> 71
Anti-Infectious Activity of the Synthetic Muramyl Dipeptide Analogue MDP-Lys (L18)	<i>K. Matsumoto, Y. Osada, T. Une, T. Otani, H. Ogawa, and I. Azuma</i> 79
The Immunomodulatory Activities of Acylpeptides	<i>T. Goto and H. Aoki</i> 99

EXPERIMENTAL APPROACHES USED TO EVALUATE CANDIDATE COMPOUNDS

Experimental Approaches for Therapeutic Use of Immunostimulants against Cancer and Infectious Diseases	<i>T. Tokunaga</i>	111
Experimental Base for the Clinical Use of Immunostimulants	<i>P. H. Lagrange</i>	123
<i>In Vivo</i> Hyperoxia as a Model of Immunosuppression	<i>M.-A. Gougerot-Pocidalo, M. Levacher, and J.-J. Pocidalo</i>	137

CLINICAL EVALUATION OF IMMUNOSTIMULANTS

Clinical Evaluation of Immunostimulants in France	<i>J.-L. Touraine</i>	147
Randomized Controlled Trials with Immunostimulants for Cancer Patients in Japan	<i>T. Ogura</i>	155
Critical Views on the Use of Immunostimulants in Cancer Treatment	<i>T. Ochiai</i>	167
Possible Models for Preliminary Clinical Immunopharmacology	<i>J.-M. Lang</i>	173
Immunostimulants in Pediatric Practice	<i>P. Reinert</i>	179
Pimelautide (R.P. 40 639). From Experimental Results to Clinical Trials: An Illustration	<i>F. Floc'h, J. Poirier, C. Fizames, and R. Woehrle</i>	183

THE FUTURE OF IMMUNOSTIMULANTS

Immunointervention in the 1990's	<i>J.-F. Bach</i>	207
The Position of Immunostimulants in Infectious Diseases	<i>E. Tsubura and Y. Kameoka</i>	217
Prospective Views on Unexplored Pathways of Immunostimulation	<i>R. M. Fauve</i>	225
Possible Role of Lymphokines and Monokines as Immunostimulating Agents	<i>J. Hamuro</i>	235
Cells and Cytokines as Immunostimulants for Cancer Specific Immunotherapy	<i>K. Kikuchi</i>	245
Conclusion	<i>Y. Yamamura</i>	251
Subject Index		255